Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model

Ingrid E. H. Kremer*, Mickael Hiligsmann, Josh Carlson, Marita Zimmermann, Peter J. Jongen, Silvia M. A. A. Evers, Svenja Petersohn, Xavier G. L. V. Pouwels, Nick Bansback

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1003-1019
Number of pages17
JournalMedical Decision Making
Volume40
Issue number8
DOIs
Publication statusPublished - Nov 2020

Keywords

  • disease-modifying drugs
  • early economic evaluation
  • multiple sclerosis
  • shared decision making
  • state transition model
  • RELEASE DIMETHYL FUMARATE
  • UNMET NEEDS TRIBUNE
  • GLATIRAMER ACETATE
  • INTERFERON BETA-1A
  • CONTROLLED PHASE-3
  • MEDICATION ADHERENCE
  • TREATMENT EXPERIENCE
  • PATIENT PREFERENCES
  • DOUBLE-BLIND
  • THERAPIES

Cite this